MBIO - Mustang Bio down 8% following data on CAR-T lymphoma asset
2023-08-16 14:22:12 ET
More on Mustang Bio
- Mustang to sell Worcester site for up to $11M, abandons some CAR T cell programs
- Mustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug status
- Seeking Alpha’s Quant Rating on Mustang Bio
For further details see:
Mustang Bio down 8% following data on CAR-T lymphoma asset